Life Sciences

This is the area where we are most careful about what we claim. Scientific discoveries can open entirely new markets, but turning one into a business takes a lot of capital, a lot of expertise and a lot of time, and plenty of good science never makes it that far.

Our research covers selected parts of life sciences, biotechnology and healthcare technology. We are drawn to the places where scientific progress, commercial potential and lasting demand meet, such as an ageing population, rising healthcare needs and technologies that change how care is delivered.

Judging these opportunities takes more than reading financial statements. Drug development is binary, slow and expensive. A trial succeeds or it doesn’t, and the outcome can change a company’s value overnight. Regulatory approval, patents, whether doctors and health systems adopt a product, and whether the team can execute all affect the result too. We have studied how that risk is priced: what a trial result is worth, how long capital has to wait, and where the odds look better or worse than the market assumes.

This is the area where we are most careful about what we claim. Scientific discoveries can open entirely new markets, but turning one into a business takes a lot of capital, a lot of expertise and a lot of time, and plenty of good science never makes it that far.

We also know where our limits are. Science at this level needs people who have spent careers in it, and we would rather say so than pretend we can judge all of it ourselves. We expect to bring in specialist advisers, and we would ask them to challenge our thinking, not just agree with it. What we hope to find is the point where an innovation becomes lasting economic value.